Bipolar Disorder and Inflammation

Psychiatric Clinics of North America

Volumn 39, Issue 1, 2016, Pages 125-137

  Rosenblat, Joshua D ^a   McIntyre, Roger S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antiinflammatory; Bipolar depression; Inflammation; Infliximab; Innate immune system; Minocycline; NAC; NSAIDs

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELECOXIB; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; LITHIUM CARBONATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; YKL40 PROTEIN; ANTIINFLAMMATORY AGENT; CYTOKINE;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CELL ACTIVATION; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LIFE EXPECTANCY; MICROGLIA; MIGRAINE; MORTALITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; COMPLICATION; IMMUNOLOGY; INNATE IMMUNITY;

ANTI-INFLAMMATORY AGENTS; BIPOLAR DISORDER; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATION;

EID: 84957842529     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2015.09.006     Document Type: Review

References (107)

1. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
2. Fagiolini A., Forgione R., Maccari M., et al. Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord 2013, 148:161-169.
3. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry 2006, 11:227-240.
4. McIntyre R.S. A vision for drug discovery and development: novel targets and multilateral partnerships. Adv Ther 2014, 31:245-246.
5. Rosenblat J.D., Cha D.S., Mansur R.B., et al. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog NeuroPsychopharmacol Biol Psychiatry 2014, 53:23-34.
6. Rosenblat J.D., McIntyre R.S. Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. Acta Psychiatr Scand 2015, 132(3):180-191.
7. Miller A.H., Haroon E., Raison C.L., et al. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013, 30:297-306.
8. Raison C.L., Miller A.H. Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun 2013, 31:1-8.
9. Horrobin D.F., Lieb J. A biochemical basis for the actions of lithium on behaviour and on immunity: relapsing and remitting disorders of inflammation and immunity such as multiple sclerosis or recurrent herpes as manic-depression of the immune system. Med Hypotheses 1981, 7:891-905.
10. Goldstein B.I., Kemp D.E., Soczynska J.K., et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70:1078-1090.
11. Munkholm K., Brauner J.V., Kessing L.V., et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013, 47:1119-1133.
12. Ayorech Z., Tracy D.K., Baumeister D., et al. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord 2015, 174:467-478.
13. Klumpers U.M., Boom K., Janssen F.M., et al. Cardiovascular risk factors in outpatients with bipolar disorder. Pharmacopsychiatry 2004, 37:211-216.
14. McIntyre R.S., Danilewitz M., Liauw S.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010, 126:366-387.
15. McIntyre R.S., Konarski J.Z., Misener V.L., et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005, 17:83-93.
16. Osby U., Brandt L., Correia N., et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58:844-850.
17. Perugi G., Quaranta G., Belletti S., et al. General medical conditions in 347 bipolar disorder patients: Clinical correlates of metabolic and autoimmune-allergic diseases. J Affect Disord 2014, 170C:95-103.
18. Swartz H.A., Fagiolini A. Cardiovascular disease and bipolar disorder: risk and clinical implications. J Clin Psychiatry 2012, 73:1563-1565.
19. Vancampfort D., Vansteelandt K., Correll C.U., et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013, 170:265-274.
20. Young A.H., Grunze H. Physical health of patients with bipolar disorder. Acta Psychiatr Scand Suppl 2013, 442:3-10.
21. Kessing L.V., Vradi E., Andersen P.K. Life expectancy in bipolar disorder. Bipolar Disord 2015, 17(5):543-548.
22. Kessing L.V., Vradi E., McIntyre R.S., et al. Causes of decreased life expectancy over the life span in bipolar disorder. J Affect Disord 2015, 180:142-147.
23. Eaton W.W., Pedersen M.G., Nielsen P.R., et al. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010, 12:638-646.
24. Bachen E.A., Chesney M.A., Criswell L.A. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009, 61:822-829.
25. Kupka R.W., Nolen W.A., Post R.M., et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002, 51:305-311.
26. Hsu C.C., Chen S.C., Liu C.J., et al. Rheumatoid arthritis and the risk of bipolar disorder: a nationwide population-based study. PLoS One 2014, 9:e107512.
27. Edwards L.J., Constantinescu C.S. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler 2004, 10:575-581.
28. Calkin C., van de Velde C., Ruzickova M., et al. Can body mass index help predict outcome in patients with bipolar disorder?. Bipolar Disord 2009, 11:650-656.
29. Lilliker S.L. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980, 21:270-275.
30. Cassidy F., Ahearn E., Carroll B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999, 156:1417-1420.
31. Han C., Lofland J.H., Zhao N., et al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011, 10:843-850.
32. Bercik P. The microbiota-gut-brain axis: learning from intestinal bacteria?. Gut 2011, 60:288-289.
33. Cryan J.F., Dinan T.G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012, 13:701-712.
34. Brietzke E., Mansur R.B., Soczynska J.K., et al. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord 2012, 140:82-91.
35. Post R.M., Altshuler L.L., Leverich G.S., et al. Role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. J Affect Disord 2013, 147:288-294.
36. Fagundes C.P., Glaser R., Kiecolt-Glaser J.K. Stressful early life experiences and immune dysregulation across the lifespan. Brain Behav Immun 2013, 27:8-12.
37. Barbosa I.G., Bauer M.E., Machado-Vieira R., et al. Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast 2014, 2014:360481.
38. Barbosa I.G., Rocha N.P., Bauer M.E., et al. Chemokines in bipolar disorder: trait or state?. Eur Arch Psychiatry Clin Neurosci 2013, 263:159-165.
39. Modabbernia A., Taslimi S., Brietzke E., et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013, 74:15-25.
40. Munkholm K., Vinberg M., Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013, 144:16-27.
41. Weller R.O., Engelhardt B., Phillips M.J. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol 1996, 6:275-288.
42. Louveau A., Smirnov I., Keyes T.J., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523:337-341.
43. Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., et al. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009, 23:1079-1082.
44. Brietzke E., Stertz L., Fernandes B.S., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009, 116:214-217.
45. Breunis M.N., Kupka R.W., Nolen W.A., et al. High numbers of circulating activated T cells and raised levels of serum IL-receptor in bipolar disorder. Biol Psychiatry 2003, 53:157-165.
46. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., et al. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011, 25:1206-1213.
47. O'Brien S.M., Scully P., Scott L.V., et al. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006, 90:263-267.
48. Barbosa I.G., Machado-Vieira R., Soares J.C., et al. The immunology of bipolar disorder. Neuroimmunomodulation 2014, 21:117-122.
49. Liu H.C., Yang Y.Y., Chou Y.M., et al. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol 2004, 150:116-122.
50. Dantzer R., O'Connor J.C., Freund G.G., et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
51. Eller T., Vasar V., Shlik J., et al. The role of IL-and soluble IL-2R in depression and antidepressant response. Curr Opin Investig Drugs 2009, 10:638-643.
52. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
53. Bauer I.E., Pascoe M.C., Wollenhaupt-Aguiar B., et al. Inflammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res 2014, 56:18-27.
54. Tse S., Chan S., Ng K.L., et al. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord 2014, 16:217-229.
55. Green M.F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006, 67(Suppl 9):3-8. [discussion: 36-42].
56. Daniel B.D., Montali A., Gerra M.L., et al. Cognitive impairment and its associations with the path of illness in affective disorders: a comparison between patients with bipolar and unipolar depression in remission. J Psychiatr Pract 2013, 19:275-287.
57. Godard J., Baruch P., Grondin S., et al. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study. Psychiatry Res 2012, 196:145-153.
58. Bourne C., Aydemir O., Balanza-Martinez V., et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013, 128:149-162.
59. Lotrich F.E., Butters M.A., Aizenstein H., et al. The relationship between interleukin-receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry 2014, 29:635-644.
60. Hamdani N., Daban-Huard C., Lajnef M., et al. Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. J Affect Disord 2015, 179:161-166.
61. Hope S., Hoseth E., Dieset I., et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res 2015, 165(2-3):188-194.
62. Dickerson F., Stallings C., Origoni A., et al. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord 2013, 150:456-459.
63. Doganavsargil-Baysal O., Cinemre B., Aksoy U.M., et al. Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol 2013, 28:160-167.
64. Barbosa I.G., Rocha N.P., Huguet R.B., et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 2012, 137:151-155.
65. Stertz L., Magalhaes P.V., Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry 2013, 26:19-26.
66. Dunn A.J., Swiergiel A.H., de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29:891-909.
67. McNamara R.K., Lotrich F.E. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?. Expert Rev Neurother 2012, 12:1143-1161.
68. Capuron L., Neurauter G., Musselman D.L., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54:906-914.
69. Arango V., Underwood M.D., Mann J.J. Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 2002, 136:443-453.
70. Buhot M.C., Martin S., Segu L. Role of serotonin in memory impairment. Ann Med 2000, 32:210-221.
71. Wang J., Dunn A.J. Mouse interleukin-stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int 1998, 33:143-154.
72. Zhang J., Terreni L., De Simoni M.G., et al. Peripheral interleukin-administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 2001, 38:303-308.
73. Ekdahl C.T. Microglial activation - tuning and pruning adult neurogenesis. Front Pharmacol 2012, 3:41.
74. Harry G.J., Kraft A.D. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 2012, 33:191-206.
75. Frick L.R., Williams K., Pittenger C. Microglial dysregulation in psychiatric disease. Clin Dev Immunol 2013, 2013:608654.
76. Haarman B.C., Riemersma-Van der Lek R.F., de Groot J.C., et al. Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 2014, 40:219-225.
77. Setiawan E., Wilson A.A., Mizrahi R., et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015, 72:268-275.
78. Rao J.S., Harry G.J., Rapoport S.I., et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010, 15:384-392.
79. Bezchlibnyk Y.B., Wang J.F., McQueen G.M., et al. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J Neurochem 2001, 79:826-834.
80. Kraft A.D., Harry G.J. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 2011, 8:2980-3018.
81. Beishuizen A., Thijs L.G. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J Endotoxin Res 2003, 9:3-24.
82. Harrison N.A., Brydon L., Walker C., et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009, 66:407-414.
83. Wright C.E., Strike P.C., Brydon L., et al. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun 2005, 19:345-350.
84. Murphy B.E. Steroids and depression. J Steroid Biochem Mol Biol 1991, 38:537-559.
85. Hoes M.J., Sijben N. The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. Psychopharmacology 1981, 75:346-349.
86. Maes M., Leonard B.E., Myint A.M., et al. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacology Biol Psychiatry 2011, 35:702-721.
87. Pace T.W., Miller A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009, 1179:86-105.
88. Turnbull A.V., Rivier C.L. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999, 79:1-71.
89. Cowen P.J. Not fade away: the HPA axis and depression. Psychol Med 2010, 40:1-4.
90. Rush A.J., Giles D.E., Schlesser M.A., et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996, 57:470-484.
91. Berk M., Copolov D.L., Dean O., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64:468-475.
92. Berk M., Dean O.M., Cotton S.M., et al. Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med 2012, 10:91.
93. Nery F.G., Monkul E.S., Hatch J.P., et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008, 23:87-94.
94. Saroukhani S., Emami-Parsa M., Modabbernia A., et al. Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. Bipolar Disord 2013, 15:650-656.
95. Stoll A.L., Severus W.E., Freeman M.P., et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999, 56:407-412.
96. Hirashima F., Parow A.M., Stoll A.L., et al. Omega-fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 2004, 161:1922-1924.
97. Keck P.E., Mintz J., McElroy S.L., et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006, 60:1020-1022.
98. Frangou S., Lewis M., McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006, 188:46-50.
99. Frangou S., Lewis M., Wollard J., et al. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol (Oxford, England) 2007, 21:435-439.
100. Zeinoddini A., Sorayani M., Hassanzadeh E., et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety 2015, 32:167-173.
101. Savitz J., Preskorn S., Teague T.K., et al. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open 2012, 2:e000643.
102. Magalhaes P.V., Dean O.M., Bush A.I., et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011, 33:374-378.
103. Berk M., Dean O., Cotton S.M., et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011, 135:389-394.
104. Bloch M.H., Hannestad J. Omega-fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2012, 17:1272-1282.
105. Kemp D.E., Schinagle M., Gao K., et al. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs 2014, 28:571-581.
106. Soczynska J.K., Mansur R.B., Brietzke E., et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 2012, 235:302-317.
107. Raison C.L., Rutherford R.E., Woolwine B.J., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.